BRAINTREE, Mass., Feb. 14, 2013 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that Vice President and Chief Medical Officer, Dr. Mark A. Popovsky, has been invited by the U.S. Department of Health & Human Services Secretary Kathleen Sebelius, to serve on the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA).
As one of nine official representative members of the blood, blood products, tissue and organ professional organizations or business sectors, Dr. Popovsky will provide counsel and advice to the Secretary, and to the Assistant Secretary for Health, on policy issues involving the availability of blood and blood products, the ethical and legal issues related to transfusions and transplantation and economic factors affecting blood product cost and supply in the United States.
"I am honored to join the Advisory Committee on Blood Safety," said Dr. Popovsky. "I look forward to this incredible opportunity to work with other industry experts to provide counsel and advice on regulations and policies to ensure the safety and availability of the U.S. blood supply."
Dr. Popovsky received his training in anatomic and clinical pathology at the National Institutes of Health and in transfusion medicine at the Mayo Clinic and served as Director of the Transfusion & Intravenous Services at the Mayo Clinic from 1982 to 1985. In 1985, Dr. Popovsky assumed the role of Medical Director of the American Red Cross – New England Region, a position he held until 1995. From 1996-2000, he was Chief Executive Officer & Chief Medical Officer of the New England Region. He has held academic appointments at Harvard Medical School and Boston University School of Medicine, and has more than 400 peer-reviewed publications in medical literature.
Dr. Popovsky's appointment went into effect January 2013 and will end December 2016. ACBTSA was established in 1997.
About Haemonetics Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our website at http://www.haemonetics.com.
CONTACTS: Gerry Gould VP-Investor Relations Tel. (781) 356-9402 email@example.com Alt. (781) 356-9613
Marisa Borgasano Schwartz MSL for Haemonetics Tel. (781) 684-0770 Haemonetics@schwartzmsl.com
SOURCE Haemonetics Corporation